Physician profile
Margaret Wong Gribble
NPI 1477723187
$342,141.94
in general payments reported to CMS, 2019-2025
30 companies · $46K in 2025
The $46K reported for 2025 was more than what 93% of Uveitis and Ocular Inflammatory Disease providers received nationally (typical 2025 total: $471).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $24K · 2021: $21K · 2022: $34K · 2023: $88K · 2024: $94K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $180K · Travel and Lodging: $32K · Food and Beverage: $11K · Consulting Fee: $5,430 · Education: $188 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $179,600.00 |
| Travel and Lodging | $32,190.01 |
| Food and Beverage | $10,985.16 |
| Consulting Fee | $5,430.00 |
| Education | $187.69 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $249,352.40 | 2020-2025 | Acthar |
| Astellas Pharma US INC | $36,590.94 | 2023-2025 | Izervay |
| Mallinckrodt Enterprises LLC | $18,493.62 | 2019 | |
| Abbvie INC. | $15,069.72 | 2019-2025 | |
| Eyepoint US, INC. | $6,909.68 | 2022-2023 | |
| Allergan, INC. | $5,794.22 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $1,943.32 | 2019-2025 | Eylea Hd, Eylea |
| Oyster Point Pharma, INC. | $1,800.00 | 2024 | |
| Genentech USA, INC. | $1,496.35 | 2019-2025 | Vabysmo, Lucentis |
| Kala Pharmaceuticals, INC. | $615.18 | 2019-2021 | |
| Alimera Sciences, INC. | $590.74 | 2019-2024 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $454.66 | 2019-2021 | |
| Biogen, INC. | $429.90 | 2022-2024 | Byooviz |
| Glaukos Corporation | $337.54 | 2023-2024 | |
| Bausch & Lomb Americas INC. | $336.55 | 2022-2025 | Miebo, Xiidra, Xipere |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $319.93 | 2023-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Apellis Pharmaceuticals, INC. | $300.65 | 2023-2025 | Syfovre |
| Horizon Therapeutics Plc | $223.72 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $162.72 | 2021 | |
| Biotissue Holdings INC. | $158.62 | 2021-2023 | |
| Astellas Pharma Global Development | $126.36 | 2025 | Izervay |
| Coherus Oncology, INC. | $121.94 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $113.12 | 2022 | |
| Spark Therapeutics, INC. | $95.73 | 2019 | |
| Alcon Vision LLC | $83.01 | 2023-2025 | Simbrinza, Rhopressa, Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $57.31 | 2021 | |
| Amgen INC. | $54.86 | 2025 | Uplizna |
| Akorn, INC. | $53.22 | 2019 | |
| Sandoz INC. | $32.50 | 2025 | Cimerli |
| Harrow Eye, LLC | $23.43 | 2025 | Iheezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Wong Gribble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.